Obesity-related kidney disease: Beyond hypertension and insulin-resistance

Chronic kidney disease (CKD) causes considerable morbidity, mortality, and health expenditures worldwide. Obesity is a significant risk factor for CKD development, partially explained by the high prevalence of diabetes mellitus and hypertension in obese patients. However, adipocytes also possess pot...

Full description

Saved in:
Bibliographic Details
Main Authors: Tarek Arabi, Areez Shafqat, Belal Nedal Sabbah, Nader Ashraf, Hassan Shah, Humzah Abdulkader, Adhil Razak, Ahmad Nedal Sabbah, Ziad Arabi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.1095211/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850146813811621888
author Tarek Arabi
Areez Shafqat
Belal Nedal Sabbah
Nader Ashraf
Hassan Shah
Humzah Abdulkader
Adhil Razak
Ahmad Nedal Sabbah
Ziad Arabi
Ziad Arabi
Ziad Arabi
author_facet Tarek Arabi
Areez Shafqat
Belal Nedal Sabbah
Nader Ashraf
Hassan Shah
Humzah Abdulkader
Adhil Razak
Ahmad Nedal Sabbah
Ziad Arabi
Ziad Arabi
Ziad Arabi
author_sort Tarek Arabi
collection DOAJ
description Chronic kidney disease (CKD) causes considerable morbidity, mortality, and health expenditures worldwide. Obesity is a significant risk factor for CKD development, partially explained by the high prevalence of diabetes mellitus and hypertension in obese patients. However, adipocytes also possess potent endocrine functions, secreting a myriad of cytokines and adipokines that contribute to insulin resistance and induce a chronic low-grade inflammatory state thereby damaging the kidney. CKD development itself is associated with various metabolic alterations that exacerbate adipose tissue dysfunction and insulin resistance. This adipose-renal axis is a major focus of current research, given the rising incidence of CKD and obesity. Cellular senescence is a biologic hallmark of aging, and age is another significant risk factor for obesity and CKD. An elevated senescent cell burden in adipose tissue predicts renal dysfunction in animal models, and senotherapies may alleviate these phenotypes. In this review, we discuss the direct mechanisms by which adipose tissue contributes to CKD development, emphasizing the potential clinical importance of such pathways in augmenting the care of CKD.
format Article
id doaj-art-eda2d8273b764b5689fb5f4ecc090b49
institution OA Journals
issn 1664-2392
language English
publishDate 2023-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-eda2d8273b764b5689fb5f4ecc090b492025-08-20T02:27:45ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-01-011310.3389/fendo.2022.10952111095211Obesity-related kidney disease: Beyond hypertension and insulin-resistanceTarek Arabi0Areez Shafqat1Belal Nedal Sabbah2Nader Ashraf3Hassan Shah4Humzah Abdulkader5Adhil Razak6Ahmad Nedal Sabbah7Ziad Arabi8Ziad Arabi9Ziad Arabi10College of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh, Saudi ArabiaDivision of Nephrology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi ArabiaKing Abdullah International Medical Research Center, Riyadh, Saudi ArabiaCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaChronic kidney disease (CKD) causes considerable morbidity, mortality, and health expenditures worldwide. Obesity is a significant risk factor for CKD development, partially explained by the high prevalence of diabetes mellitus and hypertension in obese patients. However, adipocytes also possess potent endocrine functions, secreting a myriad of cytokines and adipokines that contribute to insulin resistance and induce a chronic low-grade inflammatory state thereby damaging the kidney. CKD development itself is associated with various metabolic alterations that exacerbate adipose tissue dysfunction and insulin resistance. This adipose-renal axis is a major focus of current research, given the rising incidence of CKD and obesity. Cellular senescence is a biologic hallmark of aging, and age is another significant risk factor for obesity and CKD. An elevated senescent cell burden in adipose tissue predicts renal dysfunction in animal models, and senotherapies may alleviate these phenotypes. In this review, we discuss the direct mechanisms by which adipose tissue contributes to CKD development, emphasizing the potential clinical importance of such pathways in augmenting the care of CKD.https://www.frontiersin.org/articles/10.3389/fendo.2022.1095211/fullchronic kidney diseaseobesitycellular senescencechronic inflammationadipokinessenotherapies
spellingShingle Tarek Arabi
Areez Shafqat
Belal Nedal Sabbah
Nader Ashraf
Hassan Shah
Humzah Abdulkader
Adhil Razak
Ahmad Nedal Sabbah
Ziad Arabi
Ziad Arabi
Ziad Arabi
Obesity-related kidney disease: Beyond hypertension and insulin-resistance
Frontiers in Endocrinology
chronic kidney disease
obesity
cellular senescence
chronic inflammation
adipokines
senotherapies
title Obesity-related kidney disease: Beyond hypertension and insulin-resistance
title_full Obesity-related kidney disease: Beyond hypertension and insulin-resistance
title_fullStr Obesity-related kidney disease: Beyond hypertension and insulin-resistance
title_full_unstemmed Obesity-related kidney disease: Beyond hypertension and insulin-resistance
title_short Obesity-related kidney disease: Beyond hypertension and insulin-resistance
title_sort obesity related kidney disease beyond hypertension and insulin resistance
topic chronic kidney disease
obesity
cellular senescence
chronic inflammation
adipokines
senotherapies
url https://www.frontiersin.org/articles/10.3389/fendo.2022.1095211/full
work_keys_str_mv AT tarekarabi obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT areezshafqat obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT belalnedalsabbah obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT naderashraf obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT hassanshah obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT humzahabdulkader obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT adhilrazak obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT ahmadnedalsabbah obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT ziadarabi obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT ziadarabi obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance
AT ziadarabi obesityrelatedkidneydiseasebeyondhypertensionandinsulinresistance